CHICAGO--(BUSINESS WIRE)--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today it has reaffirmed the estimated, unaudited ranges for fiscal 2023 of GAAP Revenue, Adjusted EBITDA, and Non-GAAP diluted earnings per share that it provided on January 10, 2024, in the Company's Form 8-K filed on January 10, 2024, and initially reaffirmed on February 27, 2024. The company also introduced initial financial guidance for Fiscal 2024 as follows: (1) Please refer to the Explanation of Non-GAAP and Other Financial Measures section. In providing financial guidance, the company does not reconcile Adjusted EBITDA to the corresponding GAAP financial measure.